WW International Inc Stock Price, News & Analysis

WeightWatchers (NASDAQ: WW) has scheduled its second quarter 2025 earnings conference call. The company will release Q2 2025 financial results before market open on Tuesday, August 5, 2025. The earnings conference call will be held at 8:30 a.m. ET the same day.

Investors can access the webcast through the company's corporate website at corporate.ww.com in the Events and Presentations section. A replay will remain available on the website for at least 90 days following the call.

CheqUp and WeightWatchers (WW) have announced a strategic partnership to enhance GLP-1 medication-based weight loss services in the UK. The collaboration combines CheqUp's clinical support and health coaching with WeightWatchers' GLP-1 Companion Programme, targeting a market of 12 million UK residents qualifying for GLP-1 medications. The partnership offers CheqUp members free access to WeightWatchers' comprehensive support system, including nutritional guidance, tracking tools, and community support. Data from the U.S. shows that WeightWatchers members using obesity medications alongside their program lose 11% more weight than those using medication alone. In a study of 3,260 WeightWatchers Clinic patients, members achieved an average 21% body weight reduction at 12 months.

WeightWatchers (WW) has announced a strategic financial reorganization to eliminate $1.15 billion in debt through a pre-packaged Chapter 11 bankruptcy process. The company has secured support from 72% of its lenders and noteholders, expecting to complete the reorganization in approximately 45 days while remaining publicly traded. The transaction will reduce annual interest expenses by $50 million and maintain $175 million from its revolving credit facility. WW's operations will continue uninterrupted, with no impact on its 3+ million members worldwide. The company's telehealth business showed strong performance with 57% year-over-year revenue growth in Q1 2025. Under the agreement, lenders will receive $465 million in new senior secured debt and 91% of new common equity, while existing shareholders will receive 9% of new common equity subject to conditions.

WeightWatchers (NASDAQ: WW) has announced a crucial investor conference call scheduled for May 6, 2025, at 6:00 p.m. ET. During the call, CEO Tara Comonte and CFO Felicia DellaFortuna will discuss an agreement with the company's lenders and noteholders that is expected to lead to a voluntary prepackaged Chapter 11 bankruptcy filing. The agreement aims to significantly reduce WW's debt obligations. The conference call webcast will be available on corporate.ww.com under Events and Presentations, with a replay accessible for at least 90 days.

WW International reported Q1 2025 results showing mixed performance. The company posted revenues of $186.6 million, down 9.7% year-over-year, with total subscribers declining 14.2% to 3.4 million. However, Clinical business showed strong growth with Clinical Subscription Revenues up 57.1% to $29.5 million and Clinical Subscribers increasing 55.2%. The company recorded a net loss of $72.6 million, though this was an improvement from the prior year's loss of $347.9 million. Notably, Adjusted EBITDAS increased to $26.9 million from $7.2 million, reflecting cost management efforts. WW is currently in discussions with lenders regarding a potential prepackaged Chapter 11 bankruptcy filing to reduce debt obligations, with cash and equivalents standing at $236.3 million, including $171.3 million in revolving credit facility borrowings.

WeightWatchers has announced a strategic pharmacy integration with LillyDirect's provider Gifthealth to streamline access to Zepbound weight management medication. The partnership enables real-time prescription tracking and simplified fulfillment for WeightWatchers Clinic members through the WeightWatchers App.

Key highlights:

• 33% of WeightWatchers Clinic members currently use Zepbound
• Zepbound vial prescriptions have increased by over 100% in recent months
• A study of 3,260 WeightWatchers Clinic patients showed 21% average body weight loss at 12 months

The integration specifically benefits self-pay patients without insurance coverage by offering Zepbound vials at more affordable prices. This move aligns with WeightWatchers' holistic approach to weight management, combining medication access with their proven behavioral tools and community support system.

WW International reported Q4 2024 results with revenues of $184.4 million and net income of $25.1 million. Total subscribers reached 3.3 million, including 92,000 Clinical subscribers, up 37.8% year-over-year. While subscription revenues declined 7.3%, Clinical subscription revenues grew 57.9% to $20.5 million.

Q4 highlights include improved gross margin of 69.7% (up 906 basis points) and operating income of $36.2 million. The company appointed Tara Comonte as permanent President and CEO.

Full year 2024 showed mixed results with revenues of $785.9 million and a net loss of $345.7 million, including $293.2 million in non-cash impairment charges. The company remains focused on cost management, targeting $100 million in run-rate savings by end of 2025.

WW International (NASDAQ: WW) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 p.m. ET on the same day.

During the call, Interim President and CEO Tara Comonte and CFO Felicia DellaFortuna will discuss the results and take questions from investors. The webcast will be available on corporate.ww.com under Events and Presentations, with supplemental investor materials provided before the call. A replay will be accessible for approximately 90 days.

WeightWatchers (WW) has launched a next-generation program featuring advanced AI-powered features and expanded nutrition support. The program introduces insurance-covered access to registered dietitians, AI-powered food scanning and recipe analysis tools, and over 150 new ZeroPoint® foods. Key features include personalized nutrition counseling, macro-nutrient tracking, and seamless Points® calculation through photo recognition.

The program complements WW's recent expansion into clinical solutions, including access to weight-loss medications. Studies show members using the Points Program alongside medications achieve 56% more weight loss than those using medications alone. The company reports that members experience a 20% improvement in quality of life with their enhanced model of care.